Document Type
Oral Presentation
Location
Oxford Conference Center, Oxford MS
Event Website
https://oxfordicsb.org/
Start Date
8-4-2025 1:00 PM
Description
Cardiovascular disease is a prevalent condition that imposes a significant socioeconomic burden. Korean red ginseng, a medicinal plant traditionally used in Asia, has been suggested to potentially protect against cardiovascular dysfunction by improving blood flow. We conducted a randomized, double-blind, parallel, placebo-controlled trial to assess the effects of Korean Red Ginseng Extract Powder (G1899) on blood flow and platelet aggregation (primary endpoints) and other cardiovascular health markers (e.g., blood coagulation parameters) in healthy adults. Participants (N=108) were randomized in a 1:1:1 ratio to three groups: high dose (2000 mg G1899 per day), low dose (480 mg G1899 per day), and placebo. Participants consumed assigned study products daily for 12 weeks. This trial was approved by Sterling Institutional Review Board and was registered on clinicaltrials.gov (NCT06236243). In total, 90 participants (N=30, 31 and 29 for high dose, low dose and placebo, respectively) had sufficient data for efficacy analyses. Compared to placebo, participants in high and low dose G1899 groups showed significantly reduced platelet aggregation after 12 weeks of supplementation (P<0.01 for each comparison), while there were no between-group differences in blood coagulation parameters. No significant impact of G1899 was observed in flow-mediated dilation (as a blood flow assessment) or other assessed cardiovascular health markers. G1899 demonstrated a good safety profile, with no serious adverse events, or clinically significant shifts in safety laboratory parameters. Overall, G1899 at two dosage levels was safe for daily supplementation over 12 weeks in healthy adults. Additionally, G1899 reduced platelet aggregation without adversely affecting coagulation parameters, suggesting possible antithrombotic effect without increased bleeding risk.
Recommended Citation
Rafie, Amir, "A Randomized, Double-Blinded, Parallel, Placebo-Controlled Clinical Trial to Study the Effect and Safety of Korean Red Ginseng Extract Powder on Cardiovascular Health Markers in Healthy Adults" (2025). Oxford ICSB. 24.
https://egrove.olemiss.edu/icsb/2025_ICSB/Schedule/24
Publication Date
April 2025
Accessibility Status
Screen reader accessible, Searchable text
Included in
A Randomized, Double-Blinded, Parallel, Placebo-Controlled Clinical Trial to Study the Effect and Safety of Korean Red Ginseng Extract Powder on Cardiovascular Health Markers in Healthy Adults
Oxford Conference Center, Oxford MS
Cardiovascular disease is a prevalent condition that imposes a significant socioeconomic burden. Korean red ginseng, a medicinal plant traditionally used in Asia, has been suggested to potentially protect against cardiovascular dysfunction by improving blood flow. We conducted a randomized, double-blind, parallel, placebo-controlled trial to assess the effects of Korean Red Ginseng Extract Powder (G1899) on blood flow and platelet aggregation (primary endpoints) and other cardiovascular health markers (e.g., blood coagulation parameters) in healthy adults. Participants (N=108) were randomized in a 1:1:1 ratio to three groups: high dose (2000 mg G1899 per day), low dose (480 mg G1899 per day), and placebo. Participants consumed assigned study products daily for 12 weeks. This trial was approved by Sterling Institutional Review Board and was registered on clinicaltrials.gov (NCT06236243). In total, 90 participants (N=30, 31 and 29 for high dose, low dose and placebo, respectively) had sufficient data for efficacy analyses. Compared to placebo, participants in high and low dose G1899 groups showed significantly reduced platelet aggregation after 12 weeks of supplementation (P<0.01 for each comparison), while there were no between-group differences in blood coagulation parameters. No significant impact of G1899 was observed in flow-mediated dilation (as a blood flow assessment) or other assessed cardiovascular health markers. G1899 demonstrated a good safety profile, with no serious adverse events, or clinically significant shifts in safety laboratory parameters. Overall, G1899 at two dosage levels was safe for daily supplementation over 12 weeks in healthy adults. Additionally, G1899 reduced platelet aggregation without adversely affecting coagulation parameters, suggesting possible antithrombotic effect without increased bleeding risk.
https://egrove.olemiss.edu/icsb/2025_ICSB/Schedule/24